Of the three patients in whom discordant results involved an exon 19 deletion, an EGFR‐TKI (osimertinib) was administered to two patients as first‐line treatment and was administered to the other patient as a second‐line therapy, and these three patients showed tumor shrinkage. Here, EGFR is linked to neoplasm.